A multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial to evaluate the pharmacokinetic characteristics, efficacy, and safety of MWN105 injection in non-diabetic overweight or obese participants
Latest Information Update: 15 Sep 2025
At a glance
- Drugs MWN 105 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Shanghai Minwei Biotechnology
Most Recent Events
- 15 Sep 2025 New trial record